1 active trials 1 recruiting 1 disease areas
| Phase 2 | 1 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 2 | ||||
| NCT05896228 | Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With… | Refractory Multiple Myeloma | Recruiting | 2026-03-11 |
Multiple Myeloma (1)